Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.

Falciformispora senegalensis Madurella mycetomatis Trematosphaeria grisea complications eumycetoma incidence mycetoma mycosis risk factors skin subcutaneous tissue

Journal

Medical mycology
ISSN: 1460-2709
Titre abrégé: Med Mycol
Pays: England
ID NLM: 9815835

Informations de publication

Date de publication:
27 Jun 2024
Historique:
received: 16 09 2023
revised: 14 12 2023
accepted: 25 04 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: ppublish

Résumé

The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal priority pathogens list. This systematic review aimed to evaluate the epidemiology and impact of eumycetoma. PubMed and Web of Science were searched to identify studies published between 1 January 2011 and 19 February 2021. Studies reporting on mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence during the study time frames were selected. Overall, 14 studies were eligible for inclusion. Morbidity was frequent with moderate to severe impairment of quality of life in 60.3%, amputation in up to 38.5%, and recurrent or long-term disease in 31.8%-73.5% of patients. Potential risk factors included male gender (56.6%-79.6%), younger age (11-30 years; 64%), and farming occupation (62.1%-69.7%). Mycetoma was predominantly reported in Sudan, particularly in central Sudan (37%-76.6% of cases). An annual incidence of 0.1/100 000 persons and 0.32/100  000 persons/decade was reported in the Philippines and Uganda, respectively. In Uganda, a decline in incidence from 3.37 to 0.32/100  000 persons between two consecutive 10-year periods (2000-2009 and 2010-2019) was detected. A community-based, multi-pronged prevention programme was associated with a reduction in amputation rates from 62.8% to 11.9%. With the pre-specified criteria, no studies of antifungal drug susceptibility, mortality, and hospital lengths of stay were identified. Future research should include larger cohort studies, greater drug susceptibility testing, and global surveillance to develop evidence-based treatment guidelines and to determine more accurately the incidence and trends over time.

Identifiants

pubmed: 38935904
pii: 7700344
doi: 10.1093/mmy/myae044
pii:
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : WHO

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

Auteurs

Julia E Clark (JE)

Queensland Children's Hospital and School of Clinical Medicine, University of Queensland, St Lucia, Queensland, Australia.

Hannah Yejin Kim (HY)

Infectious Diseases Institute (Sydney ID), The University of Sydney, Camperdown, New South Wales, Australia.
Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Camperdown, New South Wales, Australia.
Department of Pharmacy, Westmead Hospital, Westmead, New South Wales, Australia.

Wendy W J van de Sande (WWJ)

Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University of Rotterdam, Rotterdam, The Netherlands.

Brendan McMullan (B)

School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Department of Infectious Diseases, Sydney Children's Hospital, Randwick, New South Wales, Australia.
National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Paul Verweij (P)

Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.

Ana Alastruey-Izquierdo (A)

Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.

Arunaloke Chakrabarti (A)

Doodhadhari Burfani Hospital and Research Institute, Haridwar, India.

Thomas S Harrison (TS)

Institute for Infection and Immunity, and Clinical Academic Group in Infection and Immunity, St. George's, University of London, and St. George's University Hospitals NHS Foundation Trust, London, UK.
MRC Centre for Medical Mycology, University of Exeter, Exeter, UK.

Felix Bongomin (F)

Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda.

Roderick J Hay (RJ)

St Johns Institute of Dermatology, King's College London, London, UK.
The International Foundation for Dermatology, London, UK.

Rita Oladele (R)

Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, Lagos, Nigeria.

Jutta Heim (J)

Global Antibiotics Research and Development Partnership Foundation, Geneva, Switzerland.

Peter Beyer (P)

Global Antibiotics Research and Development Partnership Foundation, Geneva, Switzerland.

Marcelo Galas (M)

Antimicrobial Resistance Special Program, Communicable Diseases and Environmental Determinants of Health, Pan American Health Organization, Washington, District of Columbia, USA.

Siswanto Siswanto (S)

South-East Asia Region Office, World Health Organization, New Delhi, India.

Daniel Argaw Dagne (DA)

Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.

Felipe Roitberg (F)

Department of Noncommunicable Diseases, World Health Organization, Geneva, Switzerland.

Valeria Gigante (V)

AMR Division, World Health Organization, Geneva, Switzerland.

Justin Beardsley (J)

Infectious Diseases Institute (Sydney ID), The University of Sydney, Camperdown, New South Wales, Australia.
Department of Pharmacy, Westmead Hospital, Westmead, New South Wales, Australia.
Westmead Institute for Medical Research, Westmead, New South Wales, Australia.

Hatim Sati (H)

AMR Division, World Health Organization, Geneva, Switzerland.

Jan-Willem Alffenaar (JW)

Infectious Diseases Institute (Sydney ID), The University of Sydney, Camperdown, New South Wales, Australia.
Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Camperdown, New South Wales, Australia.
Department of Pharmacy, Westmead Hospital, Westmead, New South Wales, Australia.

C Orla Morrissey (CO)

Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH